just curious how they started out, of course they had not competition, but it still took time to gain traction. With Vascepa being the superior product it too will take time but at some point their could be a PaPow month where scrips just explode.
It took GSK about 4 months to hit 5 million dollars/month in sales. Not sure how many scripts that would be since do not know the rough value/script when they launched.
For us to hit the 5MM dollar mark, we would need roughly the equivalent of 25,000 scripts for the month? At $200/wholesale acq. cost?
I'm using this as a very rough guideline in case management is tight lipped.
Wall street's avg. expects us to grow faster than this (10MM sales by EO March.)
Scripts should grow cumulatively as this months scripts renew next month along with new clients, and so forth. I'm hoping that the 10MM is an accurate forcast. I'm thinking maybe a little too high for Q1 but that we do better in Q2 than the 18MM with word of mouth and campaign in full launch. JMO. Looking forward to the call tomorrow.
Sentiment: Strong Buy
jeff the best I could come up with is that Lovaza did 154 mill in sales it's first full year maybe somebody else can did up the very early sales figures. I'm not sure how to react to the early figures I'm not in the camp that they are meaningless though 67 to 252 is a triple in a week which seems insignificant but if we can do 750 next week and so on you get my point.
I don't know how the first week went with Lovaza, but I am interested in tomorrow's Leerink presentation. I think--but do not know--that there may be a lot of samples given out, without a corresponding scrip until the samples are gone. The Jan 31 sNDA was for 120 capsule samples; translates to a month's supply. If that's the reason scrips are low, but sample outflow is high, no big deal.
Patent news was good today; NDE is still out there, and the product is clearly superior to an alternative therapy. A big move is coming; it could be several months away; could be sooner.